Microbot Medical Inc. Gains Financial Support for Growth
Microbot Medical Inc. has recently achieved a significant milestone by securing a non-dilutive grant from the Israel Innovation Authority (IIA). This funding amounts to NIS 2.15 Million, approximately $630,000 in the current exchange rate, signifying a tremendous opportunity for the company to enhance its operational capabilities.
Enhancing Manufacturing Capacity
The grant primarily aims at bolstering the company's manufacturing capabilities, which is vital for the successful market entry of the LIBERTY Endovascular Robotic System. This system is anticipated to revolutionize the field of endovascular robotics, pending the necessary marketing clearance from the U.S. Food and Drug Administration (FDA).
Validation of Technology and Market Potential
The IIA's decision marks not just a financial boost for Microbot Medical but also an acknowledgment of the company's ingenuity and the milestones it has reached thus far. The IIA considered various factors during its evaluation, including the characteristics and size of the target market and the numerous inherent advantages of a single-use, disposable robotic system.
Continuing Partnerships and Future Plans
Rachel Vaknin, Chief Financial Officer of Microbot Medical, expressed her enthusiasm regarding the new grant, emphasizing its importance in strengthening the company's balance sheet and operational plans while awaiting FDA approval. The support from IIA has been instrumental in the development of the LIBERTY System through previous grants, indicating a strong belief in Microbot's capacity to scale operations and fulfill its business goals.
About MICROBOT Medical: Redefining Robotics in Medicine
Microbot Medical Inc. is considered a leader in the pre-commercial stage of medical technology. The company is committed to redefining endovascular robotics, aiming to enhance the quality of care provided to patients across the globe. The LIBERTY System is hailed as the first-of-its-kind single-use, fully disposable endovascular robotic system, a step towards breaking down barriers in advanced robotic healthcare technology.
Outlook on Future Innovations
As Microbot Medical Inc. continues to innovate, industry experts are optimistic about the possible impacts of the LIBERTY System once it receives FDA clearance. By addressing the challenges often associated with traditional robotic systems, such as accessibility and cost, the LIBERTY system is poised to make a significant contribution to healthcare delivery.
Company's Progress and Future Releases
Microbot Medical remains focused on its strategic plans for advancing research and technology in the medical sector. Each step taken towards commercializing its innovative solutions, including the receipt of grants and ongoing regulatory processes, demonstrates the company's commitment to improving medical procedures.
Frequently Asked Questions
What is the purpose of the grant received by Microbot Medical?
The grant aims to enhance Microbot's manufacturing capabilities, helping them prepare for the commercialization of their LIBERTY Endovascular Robotic System.
How much funding did Microbot Medical receive?
Microbot Medical received a grant of NIS 2.15 Million, roughly $630,000 at the current exchange rate.
When is the LIBERTY Robotic System expected to be available?
The LIBERTY Endovascular Robotic System is pending FDA marketing clearance and is currently not available for sale in the U.S.
What innovations does Microbot Medical aim to bring to healthcare?
Microbot Medical aims to lead in the development of single-use, fully disposable robotic systems that improve patient care and enhance accessibility to robotic technologies.
Who can be contacted for investor relations?
Investors can reach out to Microbot Medical through their IR email, IR@microbotmedical.com, for inquiries about their projects and grants.
